Radionuclide therapy with radium-223 chloride. A few strokes to the patient’s portrait
Radium-223 is the 1st nuclide medicine from the group of alpha emitters, its use is associated with an increase in overall survival, a delay to bone complications and a significant improvement the quality of life, proven placebo-controlled randomized studies in patients with castration-resistant pro...
Main Authors: | V. N. Oschepkov, P. B. Zotov, R. M. Ismakov, A. M. Khazimov, I. D. Tukmanbetov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2019-01-01
|
Series: | Onkourologiâ |
Subjects: | |
Online Access: | https://oncourology.abvpress.ru/oncur/article/view/908 |
Similar Items
-
Efficacy and safety of radium-223 in routine clinical practice
by: V. B. Matveev, et al.
Published: (2021-02-01) -
Treatment sequencing in metastatic castrate-resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2014-06-01) -
SEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIES
by: A. S. Markova, et al.
Published: (2018-10-01) -
Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer
by: Giuseppe Saltalamacchia, et al.
Published: (2020-07-01) -
Radium-223 in treatment of castration-resistant prostate cancer with skeletal metastases
by: V. B. Matveev, et al.
Published: (2017-10-01)